Accuray, Inc. (ARAY) Reports First Patients Treated with New TomoEDGE Dynamic Jaws Technology

Accuray is a radiation oncology company that develops, manufactures, and sells personalized, innovative treatment solutions. The company’s leading-edge technologies deliver a full range of radiation therapy and radiosurgery treatments, helping patients to live longer, better lives.

The company announced that Heidelberg University Hospital in Germany has treated the world’s first patients with the new TomoEDGE Dynamic Jaws technology combined with VoLO Planning as part of its TomoTherapy System. Heidelberg University Hospital revealed that it successfully treated patients with both prostate and breast cancers.

The TomoEDGE technology permits sharper dose sculpting and reduces treatment time for many patients by roughly half. The result is a precise, yet faster and more customized treatment delivery that is as unique as each patient. The technology also allows those providing the treatment to spare normal tissues while increasing the efficiency of the treatment. The faster treatment time also allows hospitals and clinics to treat more patients per day.

Florian Sterzing, M.D., radiation oncologist with Heidelberg University Hospital, said, “With TomoEDGE we are now able to treat faster the entire spectrum of radiation oncology patients.” For its part, Accuray says it remains committed to providing the most advanced treatments in radiation oncology.

For additional information about Accuray and its technology, visit www.accuray.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html